J clin oncol.
First line treatment in metastatic renal cell cancer.
The first 100 words appear below.
Hahn a zachary klaassen b c neeraj agarwal a benjamin haaland a john esther a xiang y.
A systematic review and network meta analysis author links open overlay panel andrew w.
The treatment of metastatic renal cell carcinoma has been revolutionized twice in the past 12 years by data showing that vascular.
No head to head clinical trials compare contemporary first line therapies for metastatic renal cell carcinoma mrcc.
To indirectly compare the efficacy and safety of first line treatments for mrcc in the intention to treat itt population and by clinical risk group.
Many recent first line clinical trials for mrcc employed the international metastatic rcc database consortium criteria to aid in risk stratification of patients.
The therapeutic approach for renal cell carcinoma is guided by the probability of cure which i.
Pal e christopher j d.
It s also called stage iv renal cell cancer.
1 however 30 to 40 of patients will develop metastatic disease after definitive treatment of localized disease 2 3 4 although for localized disease surgical resection with curative intent has been the standard approach for metastatic rcc mrcc.
Globally the incidence and mortality of renal cell carcinoma rcc has corresponded to 403 000 new cases and 175 000 deaths.
With the advent of targeted therapies many treatment options in the first line setting of metastatic clear cell renal cell carcinoma mccrcc have emerged.
This article has no abstract.
Ye d xuechen wang a sumanta k.
The relatively rapid evolution and rate of approval for metastatic renal cell carcinoma mrcc treatments have created a degree of complexity and ambiguity to first line treatment choice.
The incidence of renal cell carcinoma rcc has steadily risen over the past 10 years and accounts for 2 3 of all adult malignancies 1 metastatic rcc mrcc is associated with a poor prognosis.
Metastatic renal cell carcinoma is cancer in your kidneys that has spread to other parts of your body.
Cancer is harder to treat after it spreads but.
Historically 5 year survival was around 8 but that is rapidly improving 2 for many years the only treatment for mrcc approved by the us food and drug administration fda was high dose interleukin.
Randomized phase ii trial of first line treatment with sorafenib versus interferon alfa 2a in patients with metastatic renal cell carcinoma.
Treatment protocols for renal cell carcinoma are provided below including treatment of localized and advanced disease and recommendations for patients with predominantly clear cell carcinoma and those with predominantly non clear cell carcinoma.
